NCT06858436View on ClinicalTrials.gov

SGLT2 Inhibitor Utilization Re-perfusion Therapy

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

June 25, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions

Acute Ischemic Stroke From Large Vessel Occlusion

Interventions

DRUG

Canagliflozin 100mg

receiving Canagliflozin 100mg QD

All Listed Sponsors

lead

Taichung Veterans General Hospital

OTHER